57
Participants
Start Date
March 29, 2013
Primary Completion Date
July 7, 2023
Study Completion Date
July 7, 2023
Nilotinib
Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.
Novartis Investigative Site, Budapest
Novartis Investigative Site, Budapest
Novartis Investigative Site, Candiolo
Novartis Investigative Site, Albany
Novartis Investigative Site, Genova
Novartis Investigative Site, Bologna
Novartis Investigative Site, Modena
Novartis Investigative Site, Lille
Novartis Investigative Site, Paris
Novartis Investigative Site, Houston
Novartis Investigative Site, Moscow
Novartis Investigative Site, Singapore
Novartis Investigative Site, Singapore
Novartis Investigative Site, Suwon
Novartis Investigative Site, Haifa
Novartis Investigative Site, Vienna
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Halifax
Novartis Investigative Site, Hamilton
Novartis Investigative Site, Toronto
Novartis Investigative Site, Hong Kong SAR
Novartis Investigative Site, Roma
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Leiden
Novartis Investigative Site, Bratislava
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Malmo
Novartis Investigative Site, Cambridge
Novartis Investigative Site, London
Novartis Investigative Site, Manchester
Novartis Investigative Site, Newcastle upon Tyne
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY